Titlebook: Resistance to Targeted Therapies in Lymphomas; Ana C. Xavier,Mitchell S. Cairo Book 2019 Springer Nature Switzerland AG 2019 lymphoma.hodg

STELL

Resistance to Proteasome Inhibitor Therapy in Non-Hodgkin Lymphoma,hly-regulated, targeted degradation of proteins. Inhibition of the proteasome system has been shown to have therapeutic potential in certain hematological malignancies. In this chapter, we will provide an overview of the ubiquitin proteasome system, focusing our discussion in the mechanisms of actio

发源

separate

,Resistance to Bruton’s Tyrosine Kinase Signaling Pathway Targeted Therapies,TK) is a key component of BCR signaling and functions as an important regulator of cell proliferation and cell survival in various B-cell lymphomas. BTK inhibitors, especially ibrutinib, have shown promising anti-tumor activity in preclinical and clinical studies. High response rates of ibrutinib we

insincerity

Resistance to Checkpoint Blockade Inhibitors and Immunomodulatory Drugs,tes, most of this therapy has continued to focus on the tumor itself, and not on the tumor microenvironment. Various cells within the tumor microenvironment have been implicated in leading to resistance to immune therapy. Through a complex system of steps, T-cells become activated after presentation

与野兽博斗者

冲突

thrombus

Mechanisms of Glucocorticoid Response and Resistance in Lymphoid Malignancies,ce in lymphoid malignancies, with a particular focus on novel therapeutic strategies currently in preclinical or clinical development that are rationally-designed to overcome GC resistance and improve clinical outcomes.

减去

祖先

GULP

Resistance to Histone Deacetylase Inhibitors in the Treatment of Lymphoma,btypes of lymphoma. However, critical resistance mechanisms are well described. Optimal efficacy of HDAC inhibitors in the treatment of lymphoma is dependent upon successful strategies to overcome drug resistance.